Introducing DAXXIFY to Mainland China
Celebrating the launch of the world's first and only peptide-powered botulinum toxin product in Mainland China
Sisram Medical, a prominent leader in the medical aesthetics industry, has made an exciting announcement regarding its injectable botulinum toxin line. The National Medical Products Administration has approved the Biologics License Application for DAXXIFY, a groundbreaking product designed to enhance the appearance of moderate to severe glabellar lines. This innovative treatment merges botulinum toxin with proprietary Peptide Exchange Technology, delivering remarkable results.
Exploring the Benefits of DAXXIFY
The effects of DAXXIFY can often be seen as early as the next day, typically within two days. Crafted for longevity, it allows for smooth skin maintenance with as few as two treatments each year, with results gradually softening over time. Users frequently report improved skin texture, effectively tackling even the most stubborn wrinkles, making it a popular choice for those seeking aesthetic improvements.
Safety and Storage Benefits
Beyond its effectiveness, DAXXIFY is notable for its safety profile. It contains no human albumin or animal-based components, significantly reducing the chances of neutralizing antibodies and allergic reactions. Additionally, it offers convenience for practitioners, as it can be stored at room temperature, with specific reconstitution storage requirements that ensure its efficacy for three days when refrigerated.
Sisram's Strategic Growth Initiatives
The registration of DAXXIFY represents a pivotal achievement for Sisram Medical, bolstering its injectable business and contributing to a holistic wellness ecosystem. The company is strategically positioned to introduce this innovative product into China's vibrant market.
Expanding Reach Through Collaborative Agreements
In conjunction with the approval, Sisram has secured a licensing agreement that grants exclusive rights for importing and selling DAXXIFY in Mainland China, Hong Kong SAR, and Macao SAR. The company has also partnered with IBSA for dermal biostimulator products and Prollenium for reputable dermal fillers, aiming to expand its presence and enhance its offerings across various Asian markets.
The Growing Injectable Market in China
The injectable market in China has experienced significant growth, currently valued at RMB33.3 billion. This remarkable expansion provides Sisram with a competitive advantage, opening up new revenue streams and strengthening its foundation for future business initiatives in the region.
Leadership's Vision for the Future
Mr. Liu Yi, Chairman and Executive Director of Sisram, emphasized the strategic importance of China, noting that the approval for DAXXIFY demonstrates their dedication to delivering high-quality products to the market. CEO Lior Dayan echoed this perspective, highlighting the importance of enhancing patient experiences and providing practitioners with effective solutions that meet contemporary aesthetic demands.
About Sisram Medical Ltd
Sisram Medical Ltd is recognized as a global consumer wellness group, offering a unique array of products and services across various domains, including energy-based devices and injectables. The company is primarily owned by Fosun Pharma, a major player in China's healthcare market. Sisram Medical made its debut on the Hong Kong Exchange in 2017, underscoring its commitment to improving lives through innovative aesthetic solutions.
Frequently Asked Questions
What is DAXXIFY?
DAXXIFY is an innovative botulinum toxin product aimed at enhancing the appearance of glabellar lines and improving skin texture.
How does DAXXIFY differ from other injectables?
DAXXIFY employs Peptide Exchange Technology, which sets it apart by enhancing efficacy and providing longer-lasting results.
What are the storage requirements for DAXXIFY?
DAXXIFY can be stored at room temperature, and once reconstituted, it should be kept refrigerated for up to 72 hours.
Who owns Sisram Medical?
Sisram Medical is primarily owned by Fosun Pharma, a leading healthcare group in China.
When was Sisram Medical listed on the stock exchange?
Sisram Medical was publicly listed on the Hong Kong Exchange in September 2017.
